Clinical Report: Impact of Radiotherapy Timing on Intracranial Outcomes
Overview
This study evaluates the impact of early versus delayed radiotherapy on overall survival (OS) and intracranial progression-free survival (iPFS) in patients with EGFR-mutated non-small cell lung cancer (NSCLC) and brain metastases treated with EGFR-TKIs.
Background
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, with brain metastases occurring in approximately 40% of patients. The timing of radiotherapy in relation to EGFR-TKI treatment is crucial.
Data Highlights
Parameter
Early RT (n=70)
Delayed RT (n=65)
iPFS (months)
14.6
10.4
Median OS (months) - Exon 19
37.5
N/A
Median OS (months) - Exon 21
25.1
N/A
Key Findings
Early RT (≤1 month) improved iPFS compared to delayed RT (>1 month) (14.6 vs. 10.4 months, p = 0.010).
Exon 19 deletions were associated with a median OS of 37.5 months, while exon 21 L858R mutations had a median OS of 25.1 months (p = 0.009).
EGFR mutation subtype and extent of metastases were significant factors influencing OS (p < 0.05).
Early RT was confirmed as an independent factor for improved iPFS in multivariate analysis (p < 0.05).
Patients with limited metastatic disease had better prognostic outcomes.
Clinical Implications
The findings suggest that early initiation of radiotherapy in conjunction with EGFR-TKIs may enhance intracranial disease control in patients with EGFR-mutated NSCLC and brain metastases. Clinicians should consider the timing of radiotherapy as a critical factor in treatment planning.
Conclusion
The study highlights the importance of early radiotherapy in improving intracranial outcomes for patients with EGFR-mutated NSCLC and brain metastases. Further research may help refine treatment protocols.
